Acute myeloid leukemia is haematological neoplasia characterized by the accumulation of transformed immature myeloid cell in bone marrow. The course of the disease is marked by poor prognosis, frequent relapse, and high disease-related mortality. In spite of improvements in its therapy, above 60% of AML patients will eventually succumb to the disease, a fact stressing the need for new therapeutic approaches for remission induction and prevention of relapse. The difficulty in treating AML is thought to arise from a chemoresistant subpopulation of leukaemia stem cells (LSCs) that are capable of maintaining and reinitiating the disease.

Since the establishment of the Josep Carreras Leukaemia Research Institute, the Leukemia Stem Cell research group led by Dr. Risueño develops a research program focused on the development of therapeutic strategies for targeting LSCs. An in silico screening was performed to search for already human-approved drugs that may differentially kill LSCs while sparing healthy hematopoietic stem cells (HSCs).

Leukos Biotech holds a license from Josep Carreras Leukaemia Research Institute covering proprietary use of a family of drugs with the potencial for diagnosing, prognosing and treating AML patients developed by Dr. Risueño's team at IJC. The lead project consists in a drug repositioning where Leukos Biotech will carry clinical phase IIa and develop a companion diagnosis kit. Additional R&D projects are in the pipeline targeting other haematological malignancies.

Currently, Leukos Biotech is interested in discussing scientific and financial partnerships and product development collaborations.